The evolution of influenza resistance and treatment

JAMA

Volumn 301, Issue 10, 2009, Pages 1066-1069

  Weinstock, David M ^a,b,c   Zuccotti, Gianna ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PROTEIN M2; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DEATH; HEALTH CARE PERSONNEL; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES; VIRUS MUTATION; VIRUS PNEUMONIA; VIRUS VIRULENCE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; INFLUENZA VIRUS A; NOTE; PATHOGENICITY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE;

EID: 62149112223     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.324     Document Type: Review

References (27)

1. Bright RA, Shay DK, Shu B, Cox NJ, Klimov Al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295(8):891-894.
2. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366(9492):1175-1181.
3. We in stock DM, Zuccotti G. Adamantane resistance in influenza A. JAMA. 2006;295(8):934-936.
4. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12(4 pt B):603-616.
5. Ives J A, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55(2):307-317.
6. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50(7):2395-2402.
7. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52(9):3284-3292.
8. D ha ran NJ, Gubareva LV, Meyer JJ, et al; Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1 N1) virus in the United States. JAMA. 2009;301(10):1034-1041.
9. Gooskens J, Jonges M, Claas ECJ, Meijer A, van den Broek PJ, Kroes ACM. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA. 2009;301(10):1042- 1046.
10. Centers for Disease Control and Prevention. CDC Issues Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance among Circulating Influenza A(H1N1) Viruses, 2008-09 Influenza Season. http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum- 00279. Accessed February 12, 2009.
11. Centers for Disease Control and Prevention. FluView: 2008-2009 Influenza Season Week ending January 31, 2009. http://www.cdc.gov/flu/weekly/.
12. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir-2008/2009 influenza season, 22 January 2009. http://www.who.int/csr/ disease/influenza/H1N120090122-final.pdf. Accessed February 12, 2009.
13. Centers for Disease Control and Prevention (CDC). Influenza activity - United States and worldwide, 2007-08 season. MMWR Morb Mortal Wkly Rep. 2008;57 (25):692-697.
14. World Health Organization. Table: Influenza A(H1 N1) Virus Resistance to Oseltamivir: Last Quarter 2007 to 2 June 2008 (Update 13 June 2008). http://www.who.int/csr/disease/influenza/ResistanceTable200806013.pdf. Accessed February 12, 2009.
15. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir- resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis. 2009;15(2):155-162.
16. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog. 2008;4(7):e1000103.
17. Baz M, Abed Y, Nehme B, Boivin G. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob Agents Chemother. 2009;53(2):791-793.
18. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453(7199):1258-1261.
19. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48(suppl 1):S3-S13.
20. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al; Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection With Avian Influenza A (H5N1) Virus. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358(3):261-273.
21. Russell CA, Jones TC, Barr IG, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science. 2008;320(5874):340-346.
22. Wang Z, Tobler S, Roayaei J, Eick A. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009;301 (9):945-953.
23. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513-2522.
24. Ohmit SE, Victor JC, Teich ER, et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008;198(3):312-317.
25. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007;(2):CD001269.
26. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;(2):CD004879.
27. Belshe RB, Edwards KM, Vesikari T, et al; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-696.